Advertisement
Advertisement
U.S. markets close in 1 hour 49 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Revolution Medicines, Inc. (RVMD)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
19.65+0.12 (+0.61%)
As of 02:11PM EDT. Market open.
Advertisement

Revolution Medicines, Inc.

700 Saginaw Drive
Redwood City, CA 94063
United States
650 481 6801
https://www.revmed.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees212

Key Executives

NameTitlePayExercisedYear Born
Dr. Mark A. Goldsmith Ph.D.CEO, Pres & Chairman1.01M2.21M1962
Mr. Jack AndersChief Financial Officer462.13kN/A1977
Ms. Margaret A. Horn J.D.COO, Gen. Counsel & Sec.773.03k1.76M1963
Dr. Stephen M. Kelsey FRC Path., FRCP, M.D.Pres of R&D773.03kN/A1961
Ms. Xiaolin WangExec. VP of Clinical Devel.582.43kN/A1971
Dr. Martin D. Burke M.D., Ph.D.Co-Founder & Chairman of Scientific Advisory BoardN/AN/AN/A
Dr. Michael A. Fischbach Ph.D.Academic Co-Founder & Member of Scientific Advisory BoardN/AN/A1981
Dr. Kevan M. Shokat Ph.D.Academic Co-Founder & Member of Scientific Advisory BoardN/AN/AN/A
Mr. David L. Pompliano Ph.D.Founding Chief Scientific OfficerN/AN/AN/A
Mr. Walter Reiher Ph.D.Chief Information OfficerN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Corporate Governance

Revolution Medicines, Inc.’s ISS Governance QualityScore as of October 1, 2022 is 7. The pillar scores are Audit: 8; Board: 6; Shareholder Rights: 8; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement